The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 ...

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to ...

Brookstone Capital Management cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 8.9% in the fourth ...

Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

In a report released today, Eve Burstein from Bernstein maintained a Buy rating on Thermo Fisher (TMO – Research Report), with a price target ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on Thermo Fisher (TMO – Research Report) today and set a price target of $647.00.

Roche plans to release the system in the US to run tests including vitamin D and steroid assays under CLIA before it possibly receives US Food and Drug Administration clearance.

The CDMO's growth strategy, capital deployment approach, and work with AI, among other things, have been key to its 2024 performance.

Gastric cancer diagnostics companies are Abbott, BD, Bio-Rad Laboratories, Roche, Siemens Healthineers, Thermo Fisher Scientific, Pillar Biosciences, ETC ...

With a market cap of $205.5 billion, Thermo Fisher Scientific Inc. (TMO) is a global leader in serving science, providing a broad range of products and services across life sciences, analytical ...

On Thursday, the U.S. Commerce Department implemented an immediate ban on exports to China of certain Liquid Chromatography / ...